Leveraging a novel antibody platform, Hummingbird Bioscience focuses on the discovery and early development of oncology drugs. Hummingbird Bioscience, is a biotech company, utilizing systems and computational systems biology to develop novel therapies for disease areas and geographies with major unmet need including cancer.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/hummingbird-bioscience
” connections=”true” suffix=””]
Hummingbirds rational antibody design technology platform including ONTarget_, mAbPredict_(computational tool that identifies epitopes) and mAbHITS_ have the ability to create monoclonal antibodies targeting the complex signalling pathways that drive cancer.
In May 2017, Hummingbird Bioscience closed a venture funding round of an undisclosed amount from DeCheng Capital.